Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19805113 | 0.96 | GUSB (0.87) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL15125098 | 0.90 | GUSB (1.00) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL19805115 | 0.90 | GUSB (0.94) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL20467120 | 0.86 | GUSB (0.82) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL19805175 | 0.84 | GUSB (0.69) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL19805179 | 0.84 | GUSB (0.69) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL20467122 | 0.82 | GUSB (0.87) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL19805183 | 0.81 | GUSB (0.62) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL19805114 | 0.78 | GUSB (0.77) | GUSBNPSR1KMT2ATSHRLMNA | |
| SCHEMBL19805087 | 0.78 | GUSB (0.77) | GUSBNPSR1KMT2ATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339178-B2 | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-05-24 | — | — | US | disclosed |
| US-20190330237-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2018142365-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018017874-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-01-25 | — | — | WO | disclosed |
| US-9334288-B2 | Selective β-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150051205-A1 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150011542-A1 | Methods of Treating Adverse Intestinal Effects of Non-Steroidal Anti-Inflammatory Drugs | UNIVERSITY OF CONNECTICUT | 2015-01-08 | — | — | US | disclosed |
| US-8557808-B2 | Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120322797-A1 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339178-B2 | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof | GUSB, ENGASE, MGAM | GUSB 1/4885NPSR1 3836/4885KMT2A 4235/4885 |
| US-20190330237-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | GUSB, ENGASE, MGAM | GUSB 1/4885NPSR1 3836/4885KMT2A 4235/4885 |
| US-20150051205-A1 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS | GUSB, SI, UNG | GUSB 1/4885NPSR1 4746/4885KMT2A 3975/4885 |
| US-20120322797-A1 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS | GUSB, UNG, SI | GUSB 1/4885NPSR1 4795/4885KMT2A 3943/4885 |
| US-20150011542-A1 | Methods of Treating Adverse Intestinal Effects of Non-Steroidal Anti-Inflammatory Drugs | SI, FABP2, ALPI | GUSB 8/4885NPSR1 2367/4885KMT2A 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.